ONCOLOGY

	Overview
	Therapeutic Program
	Gene Signatures & Assays
	Cancer Cell Lines

INFLAMMATION

	Overview
	Mouse Models
	Inflammation Cell Lines

Nuclea currently has research and development programs in two primary areas: oncology and inflammation.

Oncology: Overview

One of the most important developments in medical science over the past 50 years has been a growing understanding of the genetic differences between individuals and their susceptibility to disease and therapies. With the sequencing of the human genome and the identification of specific gene functions, our understanding of the nature of disease and its progression has increased. This observation is particularly true in the case of cancer. While there are many forms of cancer and disease mechanisms, the ability to identify specific genes and proteins that turn on or turn off certain cell functions and specific pathways in which therapies operate has greatly enhanced our understanding of disease and our ability to treat it.

Nuclea is dedicated to the identification of gene and protein Biomarkers which are associated with specific disease states. One of its principal assets is an extensive biorepository and database of associated clinical data. Utilizing the biorepository and database, Nuclea has the capability of selecting and analyzing genetic information associated with the occurrence or stage of disease, as well as responsiveness to therapy. This information has considerable value to biotechnology and pharmaceutical companies, especially in connection with clinical trials. Nuclea also has the ability to develop tests which can identify gene or protein expression profiles characteristic of specific diseases.

Nuclea has created a technology platform which can be used, inter alia, for its internal research, to perform research in collaboration with third parties, for the development of sophisticated genomic tests, and for the development of drug therapies which can be out-licensed or pursued internally through the approval process.

[  back to top  ]